Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $28.9M | $37.0M | $14.1M | $0.00 | $0.00 | $2.27M | $6.39M |
| Revenue growth | — | — | — | 27.8% | -62.0% | -100.0% | — | — | 181.5% |
| Operating income | -$16.3M | -$18.9M | -$20.7M | -$27.6M | -$84.0M | -$59.0M | -$84.5M | -$91.9M | -$122M |
| Operating margin | — | — | -71.4% | -74.5% | -597.3% | — | — | -4047.1% | -1906.4% |
| Net income | -$20.2M | -$19.2M | -$18.7M | -$26.5M | -$84.7M | -$58.0M | -$81.2M | -$83.6M | -$117M |
| Net margin | — | — | -64.8% | -71.7% | -602.0% | — | — | -3680.4% | -1834.5% |
| EPS (diluted) | -$28.79 | -$12.53 | -$2.29 | -$0.82 | -$2.47 | -$227.42 | -$53.08 | -$9.37 | -$12.48 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.6M | -$17.0M | $34.2M | -$45.2M | -$76.1M | -$53.6M | -$67.3M | -$60.1M | -$78.6M |
| Capital expenditures | $1.86M | $436K | $1.06M | $6.67M | $2.91M | $5.14M | $7.84M | $17.9M | $518K |
| Free cash flow | -$16.5M | -$17.5M | $33.2M | -$51.9M | -$79.0M | -$58.8M | -$75.1M | -$78.0M | -$79.1M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $42.2M | $200M | $220M | $79.6M | $36.3M | $36.6M | $55.6M | $21.8M |
| Total assets | — | $44.5M | $223M | $265M | $185M | $73.7M | $222M | $226M | $114M |
| Total liabilities | — | $4.12M | $55.9M | $72.2M | $54.5M | $8.91M | $51.8M | $65.8M | $62.1M |
| Long-term debt | — | $349K | $180K | — | — | — | — | — | — |
| Shareholders' equity | -$29.6M | -$48.3M | $167M | $192M | -$42.2M | -$99.0M | $170M | $160M | $51.4M |
| Retained earnings | — | -$49.1M | -$68.9M | -$95.4M | -$180M | -$102M | -$183M | -$267M | -$384M |
| Shares (wtd avg diluted) | — | 2.08M | 30.8M | 34.0M | 34.6M | 255K | 1.53M | 8.92M | 9.40M |
Every figure is extracted from Korro Bio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.